SYMYOO participated in ‘BIO KOREA 2026,’ held at COEX for three days from April 28 to 30.

 

Marking its 21st anniversary, this year’s event was held under the theme “Innovation and Breakthrough, Towards a Better Future,” bringing together 586 companies from 55 countries for exhibitions, business partnering, and conferences.

 

Participating for the second consecutive year following 2025, SYMYOO engaged with global investors, bio-industry executives, and researchers to share the latest trends in the bio-health market and promote its services through business partnering.

 

In line with the market trend shifting toward AI-driven drug discovery, SYMYOO showcased its proprietary SYNeRA^™️ Clinical Trial Management System (CTMS) alongside ‘NewTn,’ a solution from its subsidiary Dodlab.

 

BIO KOREA 2026 served as a meaningful platform for SYMYOO to raise its brand awareness, introduce new technologies, and solidify its position in the evolving bio-industry. SYMYOO will continue to foster global networking to create further business opportunities.